Skip to content

Dispersed Clinical Validation of the Hyfe Cough Monitoring System

Dispersed Clinical Validation of the Hyfe Cough Monitoring System

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06775301
Enrollment
31
Registered
2025-01-15
Start date
2025-01-02
Completion date
2025-08-29
Last updated
2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cough Frequency

Keywords

Cough monitoring

Brief summary

This study will test the accuracy of the Hyfe Cough Monitoring System. This system uses a smartwatch to record the number and pattern of coughs (like a Fitbit for cough). The investigators will compare the coughs counted by the Hyfe device with manual cough counts from environmental sounds recordings in the same period. This is a dispersed observational study and will include individuals with a variety of cough related conditions including but not limited to refractory or unexplained cough, Bronchiectasis, COPD, COVID-19, non-tuberculous mycobacterial infection, tuberculosis, or upper respiratory tract infection.

Detailed description

The Hyfe Cough Monitoring System is investigational, which means that it has not been approved by the Food and Drug Administration (FDA). This study is funded by Hyfe, Inc. and executed under the direction of Dr. Peter Small (the Investigator). The study will run until thirty (30) participants have completed the study The Primary objective is to assess the agreement in cough counting between the Hyfe Cough Monitoring System and human listeners on an hour by hour basis when used by individuals with problematic cough under common living conditions using a Bland-Altman analysis. The Hyfe Watch, along with the companion app, is part of the Hyfe Cough Monitoring System. It does not compromise the users provacy as it only retains the time of day associated with each cough. When the system detects a short explosive sound, it runs a brief snippet of that sound through a cough detection algorithm on the watch. If the algorithm deems the sound to be a cough, the device records the exact time that the cough occurred, and sends this time stamp to the companion app. The companion app does not access any personal information on the phone and is only used to collect the times at which a participant coughed from the Hyfe Watch and send them digitally to the researcher. At the end of the 24 hours monitoring period envisiones, participants will be contacted by video call and asked to download this information from the companion app and send this to the Investigator. The use of the Hyfe Cough Monitoring System will not lead to additional medical interventions or changes to medical care. In contrast, the sound recording watch will record all ambient sounds during a 24 hour period. This is necessary for the investigator to get an independent count of a participant´s coughing. As such, the sound recording watch will record conversations and those in the participant´s environment during this 24 hour period. It is important to let others in the environment know that sound is being recorded. The recordings will not be directly linked with the participant´s identity and will only be listened to by researchers who are trained in how to ensure the privacy of this data. The data collected from the sound recording watch will NOT be transferred through the internet while participants are wearing it. Audio recordings will be saved on the actual device. Investigators will download the audio recordings onto a computer after the return the devices. Recordings will then be fully deleted. Criteria for success: The goal of this study is to demonstrate the performance of the Hyfe Cough Monitoring System as a device that continually and unobtrusively monitors cough. As has been agreed upon with the FDA, There is no pre-specified performance goal for the HCMS, this information will be reported in the labeling material. Therefore, the success of this study will be judged based on demonstrating adequate precision of our endpoints as quantified by their margin of error. Thus, the study will be considered satisfactory if the following criteria are satisfied: Bland-Altman analysis: * The bootstrap confidence interval for the bias has endpoints of magnitude at most 0.5. * The endpoints of the bootstrap confidence intervals surrounding the 95% Limits of Agreement have magnitude at most 5. * The regression line fitting the Bland-Altman plot has a slope that does not differ significantly from 0. This will confirm that the hourly differences do not suffer from proportional bias. These 95% Bland-Altman Limits of Agreement (LOA) criteria correspond to the extreme acceptable differences between Hyfe's cough-second counts and those of human annotators; by requiring these limits to have magnitude at most 5, it is expected that most of the differences to have magnitude less than 5. Note that the accompanying criterion for success for the bias is that its confidence interval have endpoints of magnitude at most 0.5, so it is expected that the average difference to be close to 0.

Interventions

DIAGNOSTIC_TESTHyfe Cough Monitoring System

Smartwatch-based cough monitoring

Sponsors

University of Washington
CollaboratorOTHER
Hyfe Inc
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 21 or older * Have problematic cough defined as an expressed concern about their cough * Able to collect 24 hour auditory recording * Reside in location without unusually high noise * Willing to wear watches for 24 hours * Fluent in English * Access to a device for video calls * Have an iPhone for download of the Hyfe Companion App * Accept the Hyfe Companion App Terms of Use and Privacy Policy

Exclusion criteria

* Ongoing relationship with any company making a cough monitor * Participation in a cough monitor device study in the past 6 months * Have privacy concerns * Inability to avoid unusually loud environments * Significant antitussive therapy changes in preceding week

Design outcomes

Primary

MeasureTime frameDescription
Hour by hour cough count agreement using Bland Altman24 hoursConcordance with human annotators using Bland Altman analysis with 95%CI

Secondary

MeasureTime frameDescription
Hour by hour cough count agreement using linear analysis24 hoursConcordance with human annotators using linear analysis
Event by event cough count analysis24 hoursAgreement with human anotators in terms of sensitivity, false positive rate and positive predictive value

Other

MeasureTime frameDescription
Differential performance of Hyfe day/night24 hoursUsing Bland Altman Linear analysis Sensitivity, false positive rate and positive predictive value
Differential performance of Hyfe between individuals24 hoursUsing Bland Altman Linear analysis Sensitivity, false positive rate and positive predictive value
Differential performance of Hyfe between high, middle and low cough rates24 hoursUsing Bland Altman Linear analysis Sensitivity, false positive rate and positive predictive value

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026